Registration Dossier

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

According to Regulation (EC) No. 1907/2006, Annex X, item 8.9.1, column 2, testing of carcinogenicity is not indicated, as several studies investigating the genetic toxicity of sarcosines and sarcosinates in-vitro have shown that these substances are not genotoxic. Moreover, the chronic and subchronic repeated dose toxicity tests via the oral route conducted with both N-methyl-N-(C18-(unsaturated)alkanoyl)glycine and the structural analogue substance Sodium N-lauroylsarcosinate (CAS 137-16-6) revealed no substance-related adverse effects indicative for carcinogenicity such as hyperplasia or pre-neoplastic changes (e. g. metaplasia).

Justification for classification or non-classification